Journal September 16, 2026 6 min read

Cagrilintide: mechanism of action

Cagrilintide is a long-acting amylin receptor agonist. This page sets out its receptor pharmacology, the brainstem circuits implicated in its effects on energy balance, and the clinical pharmacology data reported to date

peptides-pro Editorial

Cagrilintide is a long-acting amylin receptor agonist developed as a once-weekly subcutaneous agent for weight management, both as monotherapy and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) [4]. It is a synthetic analogue of human amylin; the evidence reviewed here does not provide its full amino-acid sequence, molecular formula or molecular weight. The compound is not currently prescribable and remains under clinical development [1].

The mechanism work centres on the amylin receptor, a heterodimer of the calcitonin receptor (Calcr) and a receptor-activity-modifying protein, with Ramp3 being the variant most discussed in the caudal brainstem literature [3].

Research Studies

Cagrilintide and Calcr-expressing neurons of the dorsal vagal complex

A cross-species transcriptomic atlas covering more than 530,000 cells and 80 neuronal populations across rat, mouse and macaque caudal brainstem, with spatial profiling in the rat dorsal vagal complex (DVC), was generated to identify mediators of cagrilintide action [3]. The work reported that cagrilintide regulates two conserved Calcr-expressing DVC neuronal populations. Acute treatment altered gene expression in area postrema Calcr/Ramp3 neurons, but chemogenetic activation of these cells in rats did not affect long-term food intake or body weight. Long-term cagrilintide treatment in rats upregulated a separate population, and the authors identified that population as the mediator of the sustained effect on energy balance [3]. This is animal and transcriptomic evidence; it does not establish the same circuit behaviour in humans.

Cagrilintide and food intake and appetite in adults with overweight or obesity

A dedicated clinical study is examining how cagrilintide influences food intake and appetite in people with overweight or obesity, with participants randomised to cagrilintide or placebo and followed for approximately 30 weeks [8]. The registered record describes the objective rather than reporting results, so the direction and magnitude of any effect on measured intake in humans are not yet available from this source.

Cagrilintide and gastrointestinal tolerability in people who do not tolerate GLP-1 receptor agonists

A separate study is assessing the safety of cagrilintide versus placebo in adults with overweight or obesity who do not tolerate marketed GLP-1 therapies because of gastrointestinal adverse events, over a period of about 8 months [5]. This addresses whether the amylin receptor pathway can be engaged in a population that has already discontinued a GLP-1-based agent; no outcome data are given in the record.

Cagrilintide and pharmacokinetics in renal or hepatic impairment

Two studies categorised adult participants by renal or hepatic function into normal, mild, moderate or severe impairment groups and gave a single cagrilintide dose of 0.6 or 0.9 (units as reported) [4]. The reported conclusion was that renal or hepatic impairment does not affect the pharmacokinetics, safety or tolerability of subcutaneous cagrilintide. This is a human pharmacokinetic finding and is the most directly translational item in the set.

Cagrilintide and formulation comparison: single-dose blood levels

A study in adults with excess body weight compared two versions of cagrilintide, designated B and D, by measuring blood levels after administration, with participants followed for about 14 weeks [6]. The comparison is between formulations rather than between mechanisms, and the record does not report which version produced higher exposure.

Cagrilintide and formulation comparison: multiple-dose blood levels

A second study compared the same two versions, B and D, after multiple doses in adults with overweight or obesity, over approximately 6 months [7]. Together with the single-dose study, this indicates that formulation behaviour is an active question in the development programme rather than a settled property of the molecule.

Cagrilintide and comparator anti-obesity agents: network meta-analysis

A network meta-analysis examined the comparative efficacy and safety of tirzepatide, semaglutide, cagrilintide and their combination (CagriSema), noting that no direct head-to-head studies had compared all advanced anti-obesity medications [2]. The analysis is a synthesis of randomised trial data rather than a mechanistic experiment, and it is included here because it frames where cagrilintide sits relative to other incretin- and amylin-directed agents.

Cagrilintide and the CagriSema combination in type 2 diabetes

Three reports describe the fixed-dose combination of cagrilintide with semaglutide. The REIMAGINE 1 phase 3a trial assessed once-weekly CagriSema in adults with type 2 diabetes inadequately controlled on diet and exercise [10]. REIMAGINE 2 compared CagriSema with semaglutide alone or cagrilintide alone in people with type 2 diabetes, on the basis that the amylin receptor agonist and the GLP-1 receptor agonist have complementary effects on glycaemic control and body weight [11]. A further report discusses CagriSema as a new option for patients with type 2 diabetes [12]. These are combination-therapy findings and should not be read as monotherapy mechanism data.

Cagrilintide and amylin-based therapy versus placebo

A systematic review and meta-analysis evaluated amylin-based obesity therapy, covering cagrilintide and CagriSema against placebo [9]. It is a pooled efficacy and safety analysis; it does not isolate a receptor-level mechanism.

Where the evidence sits

Evidence type	What it covers	Species or population
Transcriptomic atlas with spatial profiling	Calcr/Ramp3 area postrema neurons; a second DVC population mediating long-term energy balance	Rat, mouse, macaque [3]
Single-dose pharmacokinetic studies	Effect of renal or hepatic impairment on exposure, safety, tolerability	Adults with normal to severely impaired renal or hepatic function [4]
Randomised clinical studies, records only	Food intake and appetite; tolerability in GLP-1 non-tolerators; formulation comparisons	Adults with overweight or obesity [5][6][7][8]
Pooled analyses and phase 3 combination trials	Comparative efficacy and safety; CagriSema in type 2 diabetes	Adults with obesity or type 2 diabetes [2][9][10][11][12]

The mechanistic claim with the strongest direct support is receptor-level: cagrilintide acts at amylin receptors, and the caudal brainstem Calcr-expressing populations are the identified mediators in rodent and non-human primate tissue [3]. The claim that a specific DVC population drives long-term energy balance rests on chemogenetic and expression data in rats, not on human tissue. Human data in this set are pharmacokinetic and tolerability-oriented [4], or are registered study objectives without posted results [5][6][7][8].

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.